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Abstract
Aims Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1)
receptor antagonist, facilitates weight loss in obese patients. The efﬁcacy of liraglutide as a weight loss agent among patients
with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown.
Methods and results The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF
(ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary
outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an ‘on-treatment’
analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was
61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The
median ejection fraction was 25% (25th, 75th percentile 19–32%). Liraglutide use was associated with a signiﬁcant weight
reduction [liraglutide 1.00 lbs vs. placebo 2.00 lbs; treatment difference 4.10 lbs; 95% conﬁdence interval (CI) 7.94,
0.25; P = 0.0367; percentage treatment difference2.07%, 95% CI3.86,0.28; P = 0.0237]. Similar results were seen after
multivariable adjustments. Liraglutide also signiﬁcantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo
12.0 mg/dL; treatment difference 33.1 mg/dL; 95% CI 60.7, 5.6; P = 0.019).
Conclusions Liraglutide is an efﬁcacious weight loss agent in patients with HFrEF. These ﬁndings will require further
exploration in a well-powered cardiovascular outcomes trial.
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Introduction
Obesity is common and present in up to 45% of patients with
acute and chronic heart failure (HF).1,2 Liraglutide, a
glucagon-like peptide-1 (GLP-1) receptor antagonist, has
been shown to facilitate weight loss in obese and overweight
patients irrespective of diabetes status.3,4 Liraglutide (at a
dosage of 3.0 mg/day) has been approved by the US Food
and Drug Administration (FDA) for use in chronic weight loss
management among patients with a body mass index
(BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and one or more
obesity-related co-morbidities (i.e. hypertension, diabetes,
or hyperlipidaemia).5 However, there are limited data
addressing the efﬁcacy of liraglutide as a weight loss agent
among patients with HF. The liraglutide, a GLP-1 analogue,
on left ventricular function in stable chronic HF patients with
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and without diabetes (LIVE) trial, demonstrated that
liraglutide was associated with increased weight loss
compared with placebo [ref]. In order to address this
knowledge gap, we conducted an analysis of the Functional
Impact of GLP-1 for Heart Failure Treatment (FIGHT) study6
to evaluate the hypothesis that liraglutide use was associated
with a greater reduction in weight, independent of changes in
ﬂuid status, compared with placebo.
Methods
Study overview
The primary objective of the FIGHT study was to test the
hypothesis that, compared with placebo, therapy with
liraglutide after an acute HF hospitalization would be
associated with greater clinical stability at 6 months. In
contrast to the intention-to-treat analysis pre-speciﬁed for
the FIGHT study, the present analysis focused on patients that
had at least one study visit while on study drug (‘on-
treatment’ population). The design and primary results of
the FIGHT study were previously reported.6,7 Brieﬂy, the
FIGHT study was a multicentre, double-blind, placebo-
controlled, randomized clinical trial of patients with HF and
reduced left ventricular ejection fraction (LVEF) (≤40% within
the preceding 3 months). Patients were also required to have
(i) a recent (within 14 days) HF hospitalization and (ii) a pre-
admission oral diuretic dose of at least 40 mg of furosemide
or an equivalent loop diuretic. All subjects provided written
informed consent. Key exclusion criteria were (i) recent acute
coronary syndrome or coronary intervention, (ii) intolerance
of GLP-1 agonist therapy, and (iii) severe renal, hepatic, or
pulmonary disease. The FIGHT study included patients with
and without diabetes. Overall, 300 patients were randomized
in a 1:1 ratio to receive liraglutide or placebo as a daily
subcutaneous injection. Liraglutide was titrated up to
1.8 mg/day within the ﬁrst 30 days of the trial. Study visits
occurred at days 30, 90, and 180. Participants were called
at a mean of 210 days to determine adverse event status.
The primary endpoint was a global rank score in which all
participants were ranked across three hierarchical tiers: time
to death, time to rehospitalization for HF, and time-averaged
proportional change in N-terminal pro-B-type natriuretic
peptide (NT-proBNP) level from baseline to 180 days.
Compared with placebo, liraglutide had no signiﬁcant effect
on the primary endpoint.
Endpoint deﬁnition
The primary outcome of the present analysis was the change
in body weight from baseline to last completed at least one
study visit while on study drug (representing an on-treatment
analysis). We pre-speciﬁed the following subgroups of inter-
est: BMI above and below the median, diabetes, and patients
with an FDA labelling indication for liraglutide as weight loss
therapy (BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2) and one or
more obesity-related co-morbidity (i.e. hypertension, diabe-
tes, or hyperlipidaemia). Interaction terms were used to as-
sess for possible heterogeneity in treatment effect by
subgroup. Secondary outcomes included the change in meta-
bolic parameters including HbA1c and triglyceride levels. Ad-
verse events of interest were compared between liraglutide
and placebo and included anticipated disease-related, severe
hypoglycaemic, or hyperglycaemic events. Anticipated
disease-related events included arrhythmias, sudden cardiac
death, acute coronary syndromes, worsening HF, cerebrovas-
cular events, venous thrombo-embolism, light-headedness,
pre-syncope, syncope, or worsening renal function.
Statistical analysis
Baseline characteristics between patients receiving liraglutide
vs. placebo were compared using descriptive statistics. All
categorical data were reported as frequencies and percent-
ages and continuous data as median values (with interquar-
tile range). Differences in weight, HbA1c, and triglycerides
from baseline to last completed follow-up visit were assessed
between liraglutide and placebo. To assess for weight
changes independent of ﬂuid status, the treatment differ-
ences were adjusted using (i) baseline NT-proBNP and base-
line congestion score; (ii) baseline NT-proBNP, change in
NT-proBNP from baseline to last completed visit, baseline
congestion score, and change in baseline congestion score;
and (iii) change from baseline to last completed visit NT-
proBNP and change from baseline congestion score to last
completed visit. Among patients receiving liraglutide and pla-
cebo, patients with completed data for modelling and with
weight at baseline and follow-up weight were used in the
analysis. The congestion score was composed of the follow-
ing: orthopnoea (≥2 pillows = 2 points; <2 pillows = 0 points),
and oedema (trace = 0 points; moderate = 1 point; severe = 2
points).8 SAS version 9.4 (SAS Institute Inc., Cary, NC, USA)
was used for all analyses.
Funding and manuscript presentation
The FIGHT study was funded by the Heart Failure Network of
the National Heart, Lung, and Blood Institute. The FIGHT
study was approved by the research network’s protocol re-
view committee and monitored by an independent data
and safety monitoring board. The ethics committee at each
participating site approved the trial design. Database man-
agement and statistical analysis were performed by the Duke
Clinical Research Institute. The authors take responsibility for
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the manuscript’s integrity and had control and authority over
its preparation and the decision to publish.
Results
Baseline characteristics
There were 247 patients with at least one study visit while on
study drug: 123 were receiving liraglutide and 124 were
receiving placebo (Table 1). The median age was 61 years,
and 21% (n = 53) were female. The median BMI was
32.0 kg/m2, and 58% (n = 144) had diabetes. Sixty-six per cent
(n = 162) of patients had a New York Heart Association
(NYHA) Class III while 4% (n = 9) had NYHA Class IV. The me-
dian EF was 25% (25th, 75th percentile 19–32%), and the me-
dian NT-proBNP was 1927 pg/mL (25th, 75th percentile
1037–4048 pg/mL). Baseline demographics were well bal-
anced among patients assigned to placebo vs. liraglutide, ex-
cept for HF aetiology [ischaemic cardiomyopathy; liraglutide
88% (n = 108) vs. placebo 75% (n = 93); P < 0.01] and history








Age 59.5 (49.5, 66.0) 61.0 (52.0, 68.0) 61.0 (51.0, 67.0)
Gender (Female) 23% (29) 20% (24) 21% (53)
Race (White) 61% (76) 54% (66) 57% (142)
Ethnicity (Hispanic) 9% (11) 3% (4) 6% (15)
BMI (kg/m2) 32.9 (25.4, 38.9) 31.4 (27.1, 36.1) 32.0 (26.3, 37.2)
NYHA Class
I 2% (2) 2% (2) 2% (4)
II 26% (31) 30% (36) 28% (67)
III 70% (84) 64% (78) 66% (162)
IV 3% (3) 5% (6) 4% (9)
KCCQ overall summary score 40.6 (27.6, 61.3) 43.8 (29.7, 62.5) 42.7 (28.9, 61.9)
Six-min walk distance (m) 212.9 (148.5, 311.8) 231.7 (146.3, 312.0) 222.6 (146.4, 312.0)
Weight (lbs) 216.6 (168.8, 258.7) 206.1 (178.0, 244.8) 212.6 (173.5, 250.0)**
Systolic blood pressure (mmHg) 107.0 (98.0, 118.0) 108.0 (99.0, 118.0) 107.0 (98.0, 118.0)
Heart rate (bpm) 76.0 (68.5, 88.0) 75.0 (68.0, 86.0) 76.0 (68.0, 87.0)
Heart failure duration (years) 6.2 (3.7, 10.9) 6.7 (3.4, 12.6) 6.6 (3.4, 12.0)
Ischaemic HF aetiology* % (n) 75% (93) 88% (108) 81% (201)
Hypertension % (n) 75% (93) 80% (97) 77% (190)
History of atrial ﬁbrillation % (n) 46% (57) 47% (57) 47% (114)
Diabetes % (n) 60% (75) 56% (69) 58% (144)
Chronic renal insufﬁciency* % (n) 31% (39) 45% (54) 38% (93)
Beta-blocker use % (n) 94% (117) 93% (114) 94% (231)
ACE/ARB use % (n) 73% (90) 73% (89) 73% (179)
Hydralazine use % (n) 31% (39) 31% (38) 31% (77)
Long-acting nitrate use % (n) 39% (48) 35% (43) 37% (91)
Aldosterone antagonist use % (n) 63% (78) 60% (73) 62% (151)
Loop diuretic use % (n) 100% (124) 98% (121) 99% (245)
Digoxin use % (n) 38% (47) 36% (44) 37% (91)
Calcium channel blocker use % (n) 2% (3) 7% (9) 5% (12)
Any lipid-lowering agent % (n) 75% (93) 68% (84) 72% (177)
Antiplatelet use % (n) 69% (85) 71% (87) 70% (172)
Anticoagulant use % (n) 55% (68) 50% (62) 53% (130)
Creatinine (mg/dL) % (n) 1.5 (1.2, 1.8) 1.5 (1.1, 1.8) 1.5 (1.1, 1.8)
HbA1c (%) 6.7 (6.0, 7.9) 6.6 (5.9, 7.6) 6.6 (5.9, 7.9)
Total cholesterol (mg/dL) 130.5 (108.0, 168.0) 133.5 (111.0, 165.0) 132.0 (109.0, 167.0)
HDL (mg/dL) 35.0 (28.0, 46.0) 35.5 (29.0, 49.0) 35.0 (29.0, 47.0)
LDL (mg/dL) 67.5 (57.0, 94.0) 69.0 (56.0, 96.0) 69.0 (57.0, 96.0)
Triglycerides (mg/dL) 97.5 (75.0, 145.0) 105.5 (74.0, 144.0) 101.0 (74.0, 144.0)
Core lab NT-proBNP (pg/mL) 1891.00 (1016.00, 3927.00) 1937.00 (1141.00, 4227.00) 1927.50 (1037.00, 4048.00)
Core lab cystatin C (mg/L) 1.42 (1.13, 1.81) 1.31 (1.04, 1.72) 1.35 (1.08, 1.75)
Albumin (g/dL) 3.7 (3.4, 4.1) 3.7 (3.4, 4.1) 3.7 (3.4,4.1)
Echocardiogram ejection fraction (%) 25.10 (19.00, 32.00) 25.00 (19.00, 31.28) 25.00 (19.00, 32.00)
ACE/ARB, angiotensin-converting enzyme/angiotensin-receptor blocker; BMI, body mass index; KCCQ, Kansas City Cardiomyopathy Ques-
tionnaire; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
Data reported as median with 25th and 75th percentile unless otherwise stated.
3.7 +/ 0.6.
*Signiﬁcant difference between treatments (P < 0.05).
**P = 0.6155.
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of chronic renal insufﬁciency [liraglutide 45% (n = 54) vs. pla-
cebo 31% (n = 39); P = 0.03]. Baseline weight was 206.1 lbs in
patients receiving liraglutide and 212.6 lbs in patients
receiving placebo. There was comparable adherence to the
study drugs as the distribution of ﬁnal day visits was balanced
between the placebo and liraglutide groups (Supporting
Information, Table S1). The antihyperglycaemic medication
use among patients with diabetes was balanced between
patients randomized to liraglutide vs. placebo (Supporting
Information, Table S2).
Liraglutide and weight loss
Among patients receiving liraglutide (with completed data for
modelling and with weight at baseline and follow-up weight),
the baseline weight was 208 lbs compared with 203.5 lbs at
last study visit, while in patients receiving placebo, the
baseline weight was 216.5 lbs compared with 217.0 lbs at last
study visit (Table 2). There was an overall treatment
difference between liraglutide and placebo of 4.10 lbs
[95% conﬁdence interval (CI) 7.94, 0.25; P = 0.0367;
Table 2 and Figure 1]. The percentage difference in weight
change between treatment arms was 2.07% (95% CI
3.86, 0.28; P = 0.0237). After adjustment with NT-proBNP
and baseline congestion score, the weight loss treatment
difference between liraglutide and placebo persisted
(4.19 lbs; 95% CI 8.05, 0.33; P = 0.033). After
adjustment for baseline NT-proBNP, change in NT-proBNP
from baseline to last completed visit, baseline congestion
score, and change in baseline congestion score to last study
visit, there was a numerical trend towards a weight loss
treatment difference with liraglutide (3.94 lbs; 95% CI
7.96, 0.08; P = 0.055). Similarly, after adjustment with
change from baseline to last completed visit NT-proBNP and
change from baseline congestion score, there was a
numerical trend towards a weight loss treatment difference
with liraglutide compared with placebo (3.80 lbs; 95% CI
7.82, 0.23; P = 0.064).
Body mass index did not modify the relationship between
liraglutide and weight loss (interaction P-value = 0.57;
Supporting Information, Tables S3 and S4). Furthermore, the
relationship between liraglutide and weight loss was not
modiﬁed by the presence of diabetes (interaction
P-value = 0.65) or the presence of an FDA label indication
for liraglutide as weight loss agent (interaction
P-value = 0.50).
Overall, 85 (69%) of patients in the liraglutide arm and 91
(73%) of patients in the placebo arm achieved target dosing
before the last study visit used in our analysis (Supporting
Information, Table S5). Overall, it appears that numerically,
the greatest degree of weight loss occurs with the target
dose of liraglutide (1.8 mg) (Supporting Information,
Table S6).






and 95% CI with P-value
Baseline weight (lbs) 208.0 (181.0, 244.8) 216.5 (168.3, 259.3)
Last visit weight (lbs) 203.5 (177.1, 249.4) 217.0 (175.0, 255.0)
Weight change 1.00 (9.00, 10.00) 2.00 (5.51, 11.00) 4.10 (7.94, 0.25); P = 0.0367
CI, conﬁdence interval.
Data presented as median with interquartile range unless otherwise speciﬁed.
Figure 1 Weight change frequencies associated with treatment.
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Liraglutide and change in glycaemic control and
triglycerides levels
Patients receiving liraglutide had HbA1c percentage of 6.50 at
baseline and 5.90 at last study visit. In comparison, among
patients receiving placebo, HbA1c percentage was 6.95 at
baseline and 6.60 at last study visit (Table 3). There was a sig-
niﬁcant treatment difference in HbA1c levels between
liraglutide and placebo (0.48; 95% CI 0.92, 0.04;
P = 0.033; Table 3). Furthermore, there was a signiﬁcant re-
duction in triglyceride levels between patients receiving
liraglutide vs. placebo (33.1 mg/dL; 95% CI 60.7, 5.6;
P = 0.019; Table 4).
Serious adverse events
Overall, among patients on treatment who had at least one
study visit, 6% (n = 14) of patients had a severe
hypoglycaemia event, 16% (n = 39) had a severe
hyperglycaemic event, and 59% (n = 146) had an anticipated
disease-related event. There was no difference between any
serious adverse events among patients receiving liraglutide
vs. placebo (P > 0.05 for all events; Table 5).
Discussion
Liraglutide is approved by the FDA for chronic weight manage-
ment in patients with a BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2
with weight-related co-morbidity.5 However, patients with
HF were excluded frommost of the trials evaluating liraglutide
as a weight loss agent.3,4 In this on-treatment analysis of the
FIGHT study, which enrolled patients with a recent HF hospi-
talization who have EF ≤ 40%, we identiﬁed the following ma-
jor ﬁndings: (i) liraglutide was associated with a signiﬁcantly
greater reduction in weight; (ii) liraglutide was associated with
greater control of HbA1c and triglyceride levels; and (iii) there
was no difference in the likelihood of adverse events among
patients receiving liraglutide compared with placebo. This
study has signiﬁcant ﬁndings including that liraglutide reduces
weight among patients with advanced HF over 6 months while
demonstrating improvements in HbA1c and greater reduc-
tions in triglyceride levels.
Several trials have evaluated the role of liraglutide for
chronic weight management and metabolic control in over-
weight or obese patients. The Satiety and Clinical Adiposity:
Liraglutide (SCALE) Diabetes trial randomized 846 patients
with type 2 diabetes on oral hypoglycaemics and
BMI ≥ 27.0 km/m2 to 3.0 mg of liraglutide, 1.8 mg of
liraglutide, or placebo.3 Liraglutide was associated with a sig-
niﬁcant reduction in weight compared with placebo [treat-
ment difference of liraglutide (3.0 mg) vs. placebo 4.0%;
95% CI 5.10, 2.90; liraglutide (1.8 mg) vs. placebo
2.7%; 95% CI 4.00%, 1.42%; P < 0.001 for both]. In
the SCALE Obesity and Pre-diabetes trial, 3731 patients who
did not have type 2 diabetes but had a BMI of ≥30 or
≥27 kg/m2 and dyslipidaemia or hypertension were random-
ized 2:1 to 3.0 mg liraglutide or placebo.4 At 56 weeks, pa-
tients on liraglutide lost a mean of 18.5 lbs while patients
on placebo lost 6.2 lbs (mean difference of 12 lbs;
P < 0.001). HbA1c and triglyceride levels also improved
among patients randomized to liraglutide. While more






and 95% CI with P-value
Baseline HbA1c (%) 6.50 (5.80, 7.10) 6.95 (6.00, 7.90)
Last visit HbA1c (%) 5.90 (5.70, 6.50) 6.60 (5.80, 7.90)
HbA1c change 0.30 (0.70, 0.10) 0.00 (0.70, 0.50) 0.48 (0.92, 0.04); P = 0.0328
CI, conﬁdence interval.
Data presented as median with interquartile range unless otherwise speciﬁed.






and 95% CI with P-value
Baseline triglycerides (mg/dL);
mean (25th, 75th)
103.5 (75.0, 149.0) 97.0 (78.0, 124.0)
Last visit triglycerides (mg/dL);
mean (25th, 75th)
108.0 (76.0, 152.0) 115.0 (80.0, 166.0)
Triglycerides change;
mean (25th, 75th)
7.5 (13.0, 40.0) 12.0 (12.0, 75.0) 33.1 (60.7, 5.6); P = 0.0186
CI, conﬁdence interval.
Data presented as median with interquartile range unless otherwise speciﬁed.
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modest weight loss was observed in FIGHT (4.0 lbs
treatment difference between liraglutide and placebo), the
peak dose of liraglutide was only 1.8 mg and the treatment
duration was up to 180 days in FIGHT, compared with
392 days in the SCALE Diabetes and SCALE Obesity and
Pre-diabetes trials. In addition, the SCALE Diabetes and SCALE
Obesity and Pre-diabetes trials included a background of
lifestyle modiﬁcation intervention, which was not included
in FIGHT.
The FIGHT study also signiﬁcantly differed from prior
liraglutide weight loss and cardiovascular safety trials by
enrolling a patient population at high risk for cardiovascular
events and death. In the SCALE Obesity and Pre-diabetes trial,
patients with HF and NYHA class ≥ II were excluded.4 The
Liraglutide Effect and Action in Diabetes: Evaluation of the
Cardiovascular Outcome Results (LEADER) trial randomized
9380 patients with a history of cardiovascular conditions
including chronic HF with NYHA Class II or III.9 The number
of patients with HF in the LEADER trial was greater than
the FIGHT study (14% of the trial population, n = 1350),
and there did not appear to be any signal of adverse out-
comes in this subgroup9; however, patients in the FIGHT
study were a higher risk cohort as they were required to
have a recent HF hospitalization at trial entry and a severely
reduced EF. The EF data in the LEADER trial was unknown.
Our analysis provides unique insights to the impact of
liraglutide vs. placebo in a high-risk population of patients
with low EF.
Liraglutide demonstrated favourable metabolic control
compared with placebo, as reﬂected by a signiﬁcant
reduction in HbA1c and triglyceride levels. Beyond metfor-
min, current clinical practice guidelines do not provide any
signiﬁcant guidance on therapies for glycaemic control in pa-
tients with advanced HF.10–12 Given the differences in the po-
tential underlying mechanisms between patients with HF and
diabetes, evaluation of commonly used antihyperglycaemic
therapies such as GLP-1 receptor antagonists in this patient
population is warranted.13 Our results have signiﬁcant
implications as recent studies have not evaluated the efﬁcacy
of anti-diabetic agents for glycaemic control among patients
with advanced HF.3,4,13–16
Despite the observation of weight loss and favourable
glycaemic control associated with liraglutide in our analysis,
the clinical implications remain unclear. In the LEADER trial,
liraglutide was associated with a reduction in cardiovascular
death (vs. placebo; hazard ratio 0.78; 95% CI 0.66, 0.93;
P = 0.007). However, in the LIVE trial, liraglutide was
associated with an increased risk of adverse cardiac events
(including ventricular tachycardia, atrial ﬁbrillation, acute
coronary syndrome, and worsening HF; 12 with liraglutide
vs. 3 with placebo; P = 0.04).17 Our results did align with
the ﬁnding in the LIVE trial that demonstrated that liraglutide
treatment was associated with a weight loss of 2.2 ± 3.1 kg
compared with placebo (0.0 ± 3.0 kg) (mean difference
2.2 kg; P < 0.0001). Furthermore, HbA1c was signiﬁcantly
reduced in the liraglutide arm compared with placebo (mean
difference 0.4%; P < 0.0001).17
Despite the challenges of identifying HF events in a high
risk population,18 concern was raised regarding a possible
increase in HF risk among patients with a higher BMI.19 A
subgroup analysis of the FIGHT study demonstrated a trend
towards increased risk of HF hospitalization in patients with
a BMI greater than the median.20 Our analysis suggests that
patients above and below the median BMI experience similar
weight loss with liraglutide. These results suggest a possible
discordance between weight loss and clinical outcomes in
patients with HF who have a higher BMI. An obesity paradox
has been demonstrated among patients with HF, and
unexpected weight loss among patients with chronic HF is
associated with an increased risk of death21,22; this risk






(N = 124) P-value*
Any event of interest (anticipated disease-related, severe hypoglycaemic,
or hyperglycaemic)
65% (160) 67% (83) 62% (77) 0.38
Any anticipated disease-related event 59% (146) 64% (79) 54% (67) 0.10
Arrhythmia 15% (36) 19% (23) 10% (13) 0.07
Sudden cardiac death <1% (1) 0% (0) 1% (1) 0.75
Acute coronary syndrome 1% (3) 2% (2) 1% (1) 0.43
Worsening heart failure 41% (102) 44% (54) 39% (48) 0.41
Cerebrovascular event 3% (8) 3% (4) 3% (4) 0.86
Venous thrombo-embolism 2% (5) 1% (1) 3% (4) 0.29
Light-headedness, pre-syncope, or syncope 16% (39) 17% (21) 15% (18) 0.58
Worsening renal function 12% (30) 15% (19) 9% (11) 0.11
Any severe hypoglycaemic event 6% (14) 5% (6) 6% (8) 0.59
Hyperglycaemic event 16% (39) 12% (15) 19% (24) 0.12
Any serious adverse event through Day 180 19% (47) 17% (21) 21% (26) 0.44
Any event of interest or serious adverse event through Day 180 69% (170) 69% (85) 69% (85) 0.93
Any serious adverse event through Day 210 20% (49) 18% (22) 22% (27) 0.44
*P-values based on likelihood ratio χ2 or Fisher’s mid-P.
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extends to obese patients with HF.22 Prior analyses have also
suggested that weight loss may decrease arterial stiffness23
and weight gain may be associated with increased ventricular
stiffness.24 However, the obesity paradox does not appear to
be present in patients with HF and diabetes.25 Overall, the
association between intentional weight loss in patients with
HF and reduced EF (HFrEF) has been largely unexplored.
Given the rising obesity epidemic globally, adequately power
cardiovascular outcomes studies are needed to evaluate the
potential beneﬁt or harm of behavioural and pharmacologi-
cally induced weight loss among patients with HFrEF.
In the primary intention-to-treat analysis, while liraglutide
was not statistically associated with weight loss, compared
with placebo, the trend towards a reduction in weight was
clearly evident (1.5 kg with liraglutide vs. +0.3 kg with
placebo; treatment effect 1.8 kg; P = 0.09). Similar trends
are seen among changes in triglycerides associated with
liraglutide (15 mg/dL with triglyceride vs. 39 mg/dL with
placebo; treatment effect 22 mg/dL; P = 0.08). The use of
an on-treatment analysis likely resulted in the differences
between our present results and the intention-to-treat
analysis. Our results suggest that patients who were able to
reach the target dose of liraglutide had the greatest degree
of weight loss. Because only 69% of our patients in the
liraglutide arm reach target dosing before the last visit used
in our analysis, the impact of liraglutide and weight loss
may have been underestimated.
Current HF guidelines do not provide any guidance on
whether weight loss is beneﬁcial or whether pharmacological
therapies should be used.11 Liraglutide mediates weight loss
mainly by reducing appetite and caloric intake, rather than
increasing energy expenditure.26 Heart failure is associated
with signiﬁcant catabolism and reduction in lean muscle
mass27; furthermore, patients with HF are frequently
nutritionally deﬁcient.28 While limiting nutritional intake
would be a reasonable method of weight loss for an obese
patient without HF, we speculate that such strategies in a
patient with HF may ultimately lead to adverse outcomes;
multiple observational studies have demonstrated the
adverse relationship between low BMI and increased risk of
cardiovascular outcomes.11 More data will be required to
ascertain the relationship between intentional weight loss
and outcomes in patients with HFrEF. While this was a post
hoc analysis with short follow-up to assess a relationship
between weight loss and clinical outcomes, further studies
will be needed before liraglutide can be recommended as
an agent for chronic weight management in patients with
advanced HF. While the absolute weight loss from baseline
to last study follow-up associated with liraglutide was not
as evident among patients with a BMI greater than or equal
to the median, statistically, BMI did not modify the
relationship between study treatment and weight loss.
There is a lack of high-quality randomized clinical trial
evidence on whether patients with HF should pursue weight
loss as a strategy to improve outcomes. Future randomized
controlled trials among patients with advanced HF should
evaluate whether weight loss—through a combination of
physical activity, lifestyle modiﬁcation, and pharmacological
treatment—would improve patient centric outcomes such
as symptomology, quality of life, time spent outside the
hospital, and functional status. Furthermore, these studies
should evaluate the safety of weight loss with regard to
mortality given the signals of harm seen in observational
studies.
Limitations
These results are subject to the limitations of a post hoc
analysis. The present analysis was limited to patients who
were ‘on-treatment’ and were present for at least one
follow-up visit on study medication; this subgroup may not
be reﬂective of the overall trial population, and results may
not be generalizable to the broader population of patients
with HF. Weight assessment becomes inherently challenging
in the context of ﬂuid and volume retention among patients
with HF; our analysis addressed this by adjusting for a
congestion score and NT-proBNP. We did not assess clinical
outcomes because of the short duration of follow-up and
limited number of events in the ‘on-treatment’ analysis. This
analysis also was not speciﬁcally powered to detect
difference in weight among the treatment arms. Our study
also had important strengths. Namely, as the FIGHT study
enrolled a high-risk patient population excluded from almost
all other anti-diabetic drug trials, our results provide unique
insights into the efﬁcacy of liraglutide as a weight loss agent.
Conclusions
Among patients with a recent hospitalization for HF and an
EF ≤ 40%, treatment with liraglutide was associated with a
signiﬁcant reduction in weight independent of signs and
symptoms of HF and NT-proBNP levels at baseline. In addition,
liraglutide facilitated favourable metabolic changes not
observed in untreated controls. Neither BMI nor the presence
of diabetes mellitus modiﬁed the relationship between
liraglutide and weight loss. These ﬁndings provide a basis for
a further exploration of the safety and efﬁcacy of liraglutide
as an adjunct for weight loss in overweight and obese patients
with HF in a well-powered cardiovascular outcomes trial.
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